SIR2-deficient Leishmania infantum induces a defined IFN-γ/IL-10 pattern that correlates with protection

Journal of Immunology

Volumn 179, Issue 5, 2007, Pages 3161-3170

  Silvestre, Ricardo ^a,b,d   Cordeiro Da Silva, Anabela ^a,b   Santarém, Nuno ^a,b   Vergnes, Baptiste ^d   Sereno, Denis ^d   Ouaissi, Ali ^b,c,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INSERM   (France)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; LEISHMANIA VACCINE; LIVE VACCINE; NITRIC OXIDE; PROTOZOON ANTIBODY; REACTIVE NITROGEN SPECIES; SILENT INFORMATION REGULATOR PROTEIN 2; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; SIRTUIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; IMMUNE RESPONSE; KNOCKOUT MOUSE; LEISHMANIA INFANTUM; MALE; MOUSE; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION; VISCERAL LEISHMANIASIS; ANIMAL; BLOOD; GENE DELETION; GENETICS; IMMUNOLOGY; LIVER; METABOLISM; PARASITOLOGY; SPLEEN; VIRULENCE;

ANIMALS; ANTIBODIES, PROTOZOAN; CLONAL ANERGY; GENE DELETION; INTERFERON TYPE II; INTERLEUKIN-10; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SIRTUINS; SPLEEN; T-LYMPHOCYTES; VACCINES, ATTENUATED; VIRULENCE;

EID: 34547871761     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.5.3161     Document Type: Article

References (66)

1. Badaro, R., T. C. Jones, E. M. Carvalho, D. Sampaio, S. G. Reed, A. Barral, R. Teixeira, and W. D. Johnson, Jr. 1986. New perspectives on a subclinical form of visceral leishmaniasis. J. Infect. Dis. 154: 1003-1011.
2. Desjeux, P. 1996. Leishmaniasis: public health aspects and control. Clin. Dermatol. 14: 417-423.
3. Modabber, F. 1995. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89 (Suppl. 1): 83-88.
4. Haldar, J. P., S. Ghose, K. C. Saha, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 42: 702-707.
5. Alexander, J., A. R. Satoskar, and D. G. Russell. 1999. Leishmania species: models of intracellular parasitism. J. Cell Sci. 112: 2993-3002.
6. Wilson, M. E., S. M. Jeronimo, and R. D. Pearson. 2005. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb. Pathog. 38: 147-160.
7. Cunningham, A. C. 2002. Parasitic adaptive mechanisms in infection by Leishmania. Exp. Mol. Pathol. 72: 132-141.
8. Liew, F. Y., Y. Li, and S. Millott. 1990. Tumor necrosis factor-α synergizes with IFN-γ in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145: 4306-4310.
9. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. USA 88: 7011-7015.
10. Matthews, D. J., C. L. Emson, G. J. McKenzie, H. E. Jolin, J. M. Blackwell, and A. N. McKenzie. 2000. IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol. 164: 1458-1462.
11. Alexander, J., and K. Bryson. 2005. T helper (h) 1/Th2 and Leishmania: paradox rather than paradigm. Immunol. Lett. 99: 17-23.
12. Kaye, P. M., A. J. Curry, and J. M. Blackwell. 1991. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146: 2763-2770.
13. Kemp, M., J. A. Kurtzhals, K. Bendtzen, L. K. Poulsen, M. B. Hansen, D. K. Koech, A. Kharazmi, and T. G. Theander. 1993. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61: 1069-1073.
14. + T cells which are NK1.1. Eur. J. Immunol. 25: 3298-3307.
15. Miralles, G. D., M. Y. Stoeckle, D. F. McDermott, F. D. Finkelman, and H. W. Murray. 1994. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62: 1058-1063.
16. Satoskar, A., H. Bluethmann, and J. Alexander. 1995. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63: 4894-4899.
17. Murphy, M. L., U. Wille, E. N. Villegas, C. A. Hunter, and J. P. Farrell. 2001. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 31: 2848-2856.
18. + regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
19. Belkaid, Y., K. F. Hoffmann, S. Mendez, S. Kamhawi, M. C. Udey, T. A. Wynn, and D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194: 1497-1506.
20. Handman, E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14: 229-243.
21. Rivier, D., P. Bovay, R. Shah, S. Didisheim, and J. Mauel. 1999. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunol. 21: 461-473.
22. Mitchell, G. F., E. Handman, and T. W. Spithill. 1984. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust J. Exp. Biol. Med. Sci. 62: 145-153.
23. Gorczynski, R. M. 1985. Immunization of susceptible BALB/c mice against Leishmania braziliensis, II, use of temperature-sensitive avirulent clones of parasite for vaccination purposes. Cell. Immunol. 94: 11-20.
24. + T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infect. Immun. 61: 5205-5213.
25. Daneshvar, H., G. H. Coombs, P. Hagan, and R. S. Phillips. 2003. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J. Infect. Dis. 187: 1662-1668.
26. Titus, R. G., F. J. Gueiros-Filho, L. A. de Freitas, and S. M. Beverley. 1995. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 92: 10267-10271.
27. Alexander, J., G. H. Coombs, and J. C. Mottram. 1998. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161: 6794-6801.
28. Papadopoulou, B., G. Roy, M. Breton, C. Kundig, C. Dumas, I. Fillion, A. K. Singh, M. Olivier, and M. Ouellette. 2002. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun. 70: 62-68.
29. Uzonna, J. E., G. F. Spath, S. M. Beverley, and P. Scott. 2004. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172: 3793-3797.
30. Frye, R. A. 2000. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273: 793-798.
31. Gasser, S. M., and M. M. Cockell. 2001. The molecular biology of the SIR proteins. Gene 279: 1-16.
32. Brachmann, C. B., J. M. Sherman, S. E. Devine, E. E. Cameron, L. Pillus, and J. D. Boeke. 1995. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev. 9: 2888-2902.
33. Tsukamoto, Y., J. Kato, and H. Ikeda. 1997. Silencing factors participate in DNA repair and recombination in Saccharomyces cerevisiae. Nature 388: 900-903.
34. Kaeberlein, M., M. McVey, and L. Guarente. 1999. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 13: 2570-2580.
35. Tissenbaum, H. A., and L. Guarente. 2001. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410: 227-230.
36. Yahiaoui, B., A. Taibi, and A. Ouaissi. 1996. A Leishmania major protein with extensive homology to silent information regulator 2 of Saccharomyces cerevisiae. Gene 169: 115-118.
37. Vergnes, B., D. Sereno, J. Tavares, A. Cordeiro-da-Silva, L. Vanhille, N. Madjidian-Sereno, D. Depoix, A. Monte-Alegre, and A. Ouaissi. 2005. Targeted disruption of cytosolic SIR2 deacetylase discloses its essential role in Leishmania survival and proliferation. Gene 363: 85-96.
38. Onyango, P., I. Celic, J. M. McCaffery, J. D. Boeke, and A. P. Feinberg. 2002. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc. Natl. Acad. Sci. USA 99: 13653-13658.
39. Adriano, M. A., B. Vergnes, J. Poncet, F. Mathieu-Daude, A. C. da Silva, A. Ouaissi, and D. Sereno. 2007. Proof of interaction between Leishmania SIR2RP1 deacetylase and chaperone HSP83. Parasitol. Res. 100: 811-818.
40. Buffet, P. A., A. Sulahian, Y. J. Garin, N. Nassar, and F. Derouin. 1995. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39: 2167-2168.
41. Cordeiro-Da-Silva, A., M. C. Borges, E. Guilvard, and A. Ouaissi. 2001. Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation. Infect. Immun. 69: 6588-6596.
42. + T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol. 25: 569-579.
43. Rodgers, M. R., S. J. Popper, and D. F. Wirth. 1990. Amplification of kinetoplast DNA as a tool in the detection and diagnosis of Leishmania. Exp. Parasitol. 71: 267-275.
44. Carvalho, E. M., R. S. Teixeira, and W. D. Johnson, Jr. 1981. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect. Immun. 33: 498-500.
45. Sadick, M. D., R. M. Locksley, C. Tubbs, and H. V. Raff. 1986. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-γ in response to Leishmania antigens in vitro. J. Immunol. 136: 655-661.
46. Rodrigues Junior, V., J. S. Da Silva, and A. Campos-Neto. 1992. Selective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens. Parasite Immunol. 14: 49-58.
47. Bunn-Moreno, M. M., E. D. Madeira, K. Miller, J. A. Menezes, and A. Campos-Neto. 1985. Hypergammaglobulinaemia in Leishmania donovani infected hamsters: possible association with a polyclonal activator of B cells and with suppression of T cell function. Clin. Exp. Immunol. 59: 427-434.
48. Vasconcellos, R. C., K. P. Urago, M. M. Bunn-Moreno, and E. D. Madeira. 1996. Suppressor activity in Leishmania donovani-infected hamster serum: reversion by delipidated bovine serum albumin and role in cell cycle events. Braz. J. Med. Biol. Res. 29: 615-622.
49. Wei, X. Q., I. G. Charles, A. Smith, J. Ure, G. J. Feng, F. P. Huang, D. Xu, W. Muller, S. Moncada, and F. Y. Liew. 1995. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375: 408-411.
50. Bousoffara, T., H. Louzir, A. Ben Salah, and K. Dellagi. 2004. Analysis of granzyme B activity as a surrogate marker of Leishmania-specific cell-mediated cytotoxicity in zoonotic cutaneous leishmaniasis. J. Infect. Dis. 189: 1265-1273.
51. Ravindran, R., and N. Ali. 2004. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis. Curr. Mol. Med. 4: 697-709.
52. Handman, E. 1997. Leishmania vaccines: old and new. Parasitol. Today 13: 236-238.
53. Mukherjee, P., A. K. Ghosh, and A. C. Ghose. 2003. Infection pattern and immune response in the spleen and liver of BALB/c mice intracardially infected with Leishmania donovani amastigotes. Immunol. Lett. 86: 131-138.
54. Rolao, N., C. Melo, and L. Campino. 2004. Influence of the inoculation route in BALB/c mice infected by Leishmania infantum. Acta. Trop. 90: 123-126.
55. Holaday, B. J., M. M. Pompeu, T. Evans, D. N. Braga, M. J. Texeira, Q. Sousa Ade, M. D. Sadick, A. W. Vasconcelos, J. S. Abrams, R. D. Pearson, et al. 1993. Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi. J. Infect. Dis. 167: 411-417.
56. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kaplan, and R. L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70: 6284-6293.
57. Fiorentino, D. F., A. Zlotnik, P. Vieira, T. R. Mosmann, M. Howard, K. W. Moore, and A. O'Garra. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146: 3444-3451.
58. Stober, C. B., U. G. Lange, M. T. Roberts, A. Alcami, and J. M. Blackwell. 2005. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J. Immunol. 175: 2517-2524.
59. Stager, S., J. Alexander, K. C. Carter, F. Brombacher, and P. M. Kaye. 2003. Both interleukin-4 (IL-4) and IL-4 receptor α signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect. Immun. 71: 4804-4807.
60. Murray, H. W., and C. F. Nathan. 1999. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189: 741-746.
61. Evans, T. G., S. S. Reed, and J. B. Hibbs, Jr. 1996. Nitric oxide production in murine leishmaniasis: correlation of progressive infection with increasing systemic synthesis of nitric oxide. Am. J. Trop. Med. Hyg. 54: 486-489.
62. Mattner, J., N. Donhauser, G. Werner-Felmayer, and C. Bogdan. 2006. NKT cells mediate organ-specific resistance against Leishmania major infection. Microbes Infect. 8: 354-362.
63. Basu, R., S. Bhaumik, J. M. Basu, K. Naskar, T. De, and S. Roy. 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 174: 7160-7171.
64. Pinelli, E., R. M. Gonzalo, C. J. Boog, V. P. Rutten, D. Gebhard, G. del Real, and E. J. Ruitenberg. 1995. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur. J. Immunol. 25: 1594-1600.
65. Barral-Netto, M., A. Barral, C. Brodskyn, E. M. Carvalho, and S. G. Reed. 1995. Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol. 17: 21-28.
66. + effector cells default to the Th2 pathway in interferon γ-deficient mice infected with Leishmania major. J. Exp. Med. 179: 1367-1371.